Knee osteoarthritis - Pipeline Insight, 2024

This “Knee osteoarthritis - Pipeline Insight, 2024,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Knee osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Knee osteoarthritis Understanding

Knee osteoarthritis: Overview

Knee osteoarthritis is defined by degeneration of the knee’s articular cartilage - the flexible, slippery material that normally protects bones from joint friction and impact. The condition also involves changes to the bone underneath the cartilage and can affect nearby soft tissues. The defining feature of osteoarthritis is the breakdown and loss of articular cartilage. In the knee, articular cartilage covers the top of the tibia (shinbone), the bottom of the femur (thigh bone) and the back of the patella (kneecap). Articular cartilage protects the surfaces of these bones where they meet at the joint.

Knee osteoarthritis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Knee osteoarthritis pipeline landscape is provided which includes the disease overview and Knee osteoarthritis treatment guidelines. The assessment part of the report embraces, in depth Knee osteoarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Knee osteoarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Knee osteoarthritis R&D. The therapies under development are focused on novel approaches to treat/improve Knee osteoarthritis.

Knee osteoarthritis Emerging Drugs Chapters

This segment of the Knee osteoarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Knee osteoarthritis Emerging Drugs

JTA-004: Bone TherapeuticsJTA-004 is Bone Therapeutics’ next generation of intra-articular injectable, which is currently in phase III development for the treatment of osteoarthritic pain in the knee. Consisting of a unique patented mix of plasma proteins, hyaluronic acid - a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain.

MM-II: Moebius MedicalMoebius’s lead product, MM-II, is a novel non-opioid intra-articular injection that leverages the physical properties of proprietary multilamellar liposomes and an innovative mechanism-of-action to provide sustainable relief of symptomatic knee pain in osteoarthritic patients. The drug is currently in phase II stage of development.

Knee osteoarthritis: Therapeutic Assessment

This segment of the report provides insights about the different Knee osteoarthritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Knee osteoarthritis

There are approx. 40+ key companies which are developing the therapies for Knee osteoarthritis. The companies which have their Knee osteoarthritis drug candidates in the most advanced stage, i.e. phase III include, Bone Therapeutics.

Phases

This report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Knee osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Knee osteoarthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Knee osteoarthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Knee osteoarthritis drugs.

Knee osteoarthritis Report Insights

• Knee osteoarthritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Knee osteoarthritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Knee osteoarthritis drugs?
• How many Knee osteoarthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Knee osteoarthritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Knee osteoarthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Knee osteoarthritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bone Therapeutics
• Moebius Medical
• UnicoCell Biomed CO. LTD
• Gwo Xi Stem Cell Applied Technology
• Bioventus LLC
• CAR-T (Shanghai) Biotechnology
• Novartis
• Personalized Stem Cells
• Centrexion Therapeutics
• Akan Biosciences
• Samumed LLC
• Purdue Pharma
• Anika Therapeutics
• Peptinov SAS
• Flexion Therapeutics
• Centrexion Therapeutics
• Taiwan Liposome Company
• Techfields Pharma
• AstraZeneca
• Ampio Pharmaceuticals
• BioIntegrate
• Sorrento Therapeutics
• Swiss Medica XXI Century S.A.
• OrthoTrophix
• R-Bio
• Amzell
• Eupraxia Pharmaceuticals
• Meluha Life Sciences SDN BHD
• Vivex Biomedical
• Orient Europharma Co., Ltd.
• Paradigm Biopharmaceuticals
• Abbvie
• Galapagos NV
• Regeneron Pharmaceuticals
• Xalud Therapeutics
• Yooyoung Pharmaceutical
• Eupraxia Pharmaceuticals
• Celltex Therapeutics Corporation
• Eli Lilly and Company
• Sclnow Biotechnology
• Mestex AG
• Mitsubishi Tanabe Pharma Corporation
• Propella Therapeutics
• PT. Prodia Stem Cell Indonesia

Key Products

• JTA-004
• MM-II
• Elixcyte
• GXCPC1
• PTP-001
• Canakinumab
• LNA043
• PSC-01
• CNTX-4975-05
• StroMel
• Lorecivivint
• V120083
• Cingal
• PPV-06
• FX201
• CNTX-4975-05
• TLC599
• X0002
• MEDI7352
• Ampion
• Resiniferatoxin
• TPX 100
• AMZ001
• EP-104IAR
• Chondrogen
• 2ccPA
• Adalimumab
• Fasinumab
• XT-150
• YYD302
• EP-104IAR
• LRX712
• Celltex- AdMSCs
• Tanezumab
• Lopain
• MT-5547

This product will be delivered within 1-3 business days.